IL1B and atherosclerosis: TheCanakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) demonstratedreduction of cardiovascular events in patients with atherosclerosis with the useof neutralizing interleukin-1 beta (Il-1beta) [55].